Advertisement

Journal of Neurology

, Volume 261, Issue 11, pp 2234–2243 | Cite as

Inherited disorders of the neuromuscular junction: an update

  • Pedro M. Rodríguez Cruz
  • Jacqueline Palace
  • David BeesonEmail author
Neurological Update

Abstract

Congenital myasthenic syndromes (CMSs) are a group of heterogeneous inherited disorders caused by mutations in genes affecting the function and structure of the neuromuscular junction. This review updates the reader on established and novel subtypes of congenital myasthenia, and the treatment strategies for these increasingly heterogeneous disorders. The discovery of mutations associated with the N-glycosylation pathway and in the family of serine peptidases has shown that causative genes encoding ubiquitously expressed molecules can produce defects at the human neuromuscular junction. By contrast, mutations in lipoprotein-like receptor 4 (LRP4), a long-time candidate gene for congenital myasthenia, and a novel phenotype of myasthenia with distal weakness and atrophy due to mutations in AGRN have now been described. In addition, a pathogenic splicing mutation in a nonfunctional exon of CHRNA1 has been reported emphasizing the importance of analysing nonfunctional exons in genetic analysis. The benefit of salbutamol and ephedrine alone or combined with pyridostigmine or 3,4-DAP is increasingly being reported for particular subtypes of CMS.

Keywords

Congenital myasthenia Congenital myasthenic syndromes Neuromuscular junction N-glycosylation pathway Salbutamol Ephedrine Prolyl-endopeptidase-like gene (PREPL) deficiency Congenital myopathies Agrin 

Notes

Acknowledgments

We gratefully acknowledge the UK National Specialised Commissioning Team for funding to the Diagnostic and Advisory service for CMS in Oxford.

Conflicts of interest

None.

References

  1. 1.
    Palace J, Beeson D (2008) The congenital myasthenic syndromes. J Neuroimmunol 201–202:2–5CrossRefPubMedGoogle Scholar
  2. 2.
    Belaya K, Finlayson S, Slater CR et al (2012) Mutations in DPAGT1 cause a limb-girdle congenital myasthenic syndrome with tubular aggregates. Am J Hum Genet 91:193–201PubMedCentralCrossRefPubMedGoogle Scholar
  3. 3.
    Senderek J, Müller JS, Dusl M et al (2011) Hexosamine biosynthetic pathway mutations cause neuromuscular transmission defect. Am J Hum Genet 88:162–172PubMedCentralCrossRefPubMedGoogle Scholar
  4. 4.
    Cossins J, Belaya K, Hicks D et al (2013) Congenital myasthenic syndromes due to mutations in ALG2 and ALG14. Brain 136:944–956PubMedCentralCrossRefPubMedGoogle Scholar
  5. 5.
    Chaouch A, Beeson D, Hantaï D, Lochmüller H (2012) 186th ENMC international workshop: congenital myasthenic syndromes 24–26 June 2011, Naarden, The Netherlands. Neuromuscul Disord 22:566–576CrossRefPubMedGoogle Scholar
  6. 6.
    Engel AG (2012) Current status of the congenital myasthenic syndromes. Neuromuscul Disord 22:99–111PubMedCentralCrossRefPubMedGoogle Scholar
  7. 7.
    Finlayson S, Beeson D, Palace J (2013) Congenital myasthenic syndromes: an update. Pract Neurol 13:80–91CrossRefPubMedGoogle Scholar
  8. 8.
    Webster R, Maxwell S, Spearman H et al (2012) A novel congenital myasthenic syndrome due to decreased acetylcholine receptor ion-channel conductance. Brain 135:1070–1080CrossRefPubMedGoogle Scholar
  9. 9.
    Zhu H, Pytel P, Gomez CM (2014) Selective inhibition of caspases in skeletal muscle reverses the apoptotic synaptic degeneration in slow-channel myasthenic syndrome. Hum Mol Genet 23:69–77CrossRefPubMedGoogle Scholar
  10. 10.
    Chaouch A, Müller JS, Guergueltcheva V et al (2012) A retrospective clinical study of the treatment of slow-channel congenital myasthenic syndrome. J Neurol 259:474–481CrossRefPubMedGoogle Scholar
  11. 11.
    Webster RG, Cossins J, Lashley D et al (2013) A mouse model of the slow channel myasthenic syndrome: Neuromuscular physiology and effects of ephedrine treatment. Exp Neurol 248:286–298CrossRefPubMedGoogle Scholar
  12. 12.
    Palace J, Lashley D, Bailey S et al (2012) Clinical features in a series of fast channel congenital myasthenia syndrome. Neuromuscul Disord 22:112–117CrossRefPubMedGoogle Scholar
  13. 13.
    Shen X-M, Brengman JM, Edvardson S et al (2012) Highly fatal fast-channel syndrome caused by AChR ε subunit mutation at the agonist binding site. Neurology 79:449–454PubMedCentralCrossRefPubMedGoogle Scholar
  14. 14.
    Shen X, Brengman JM, Sine SM, Engel AG (2012) Myasthenic syndrome AChR α C-loop mutant disrupts initiation of channel gating. J Clin Invest 122:2613–2621PubMedCentralCrossRefPubMedGoogle Scholar
  15. 15.
    Webster R, Liu W-W, Chaouch A et al (2013) Fast-channel congenital myasthenic syndrome with a novel acetylcholine receptor mutation at the α-ε subunit interface. Neuromuscul Disord 24:143–147CrossRefPubMedGoogle Scholar
  16. 16.
    Mukhtasimova N, Sine SM (2007) An intersubunit trigger of channel gating in the muscle nicotinic receptor. J Neurosci 27:4110–4119CrossRefPubMedGoogle Scholar
  17. 17.
    Rahman MA, Masuda A, Ohe K et al (2013) HnRNP L and hnRNP LL antagonistically modulate PTB-mediated splicing suppression of CHRNA1 pre-mRNA. Sci Rep 3:2931PubMedCentralCrossRefPubMedGoogle Scholar
  18. 18.
    Park J, Mott M, Williams T, et al. (2014) Neurobiology of disease a single mutation in the acetylcholine receptor δ-subunit causes distinct effects in two types of neuromuscular synapses. 34:10211–10218Google Scholar
  19. 19.
    Punga AR, Maj M, Lin S et al (2011) MuSK levels differ between adult skeletal muscles and influence postsynaptic plasticity. Eur J Neurosci 33:890–898CrossRefPubMedGoogle Scholar
  20. 20.
    DeChiara TM, Bowen DC, Valenzuela DM et al (1996) The receptor tyrosine kinase MuSK is required for neuromuscular junction formation in vivo. Cell 85:501–512CrossRefPubMedGoogle Scholar
  21. 21.
    Mihaylova V, Salih MaM, Mukhtar MM et al (2009) Refinement of the clinical phenotype in musk-related congenital myasthenic syndromes. Neurology 73:1926–1928CrossRefPubMedGoogle Scholar
  22. 22.
    Chevessier F, Faraut B, Ravel-Chapuis A et al (2005) Pathophysiological characterization of congenital myasthenic syndromes: the example of mutations in the MUSK gene. J Soc Biol 199:61–77CrossRefPubMedGoogle Scholar
  23. 23.
    Maselli Ra, Arredondo J, Cagney O et al (2010) Mutations in MUSK causing congenital myasthenic syndrome impair MuSK-Dok-7 interaction. Hum Mol Genet 19:2370–2379PubMedCentralCrossRefPubMedGoogle Scholar
  24. 24.
    Gallenmüller C, Felber WM, Dusl M et al (2014) Salbutamol-responsive limb-girdle congenital myasthenic syndrome due to a novel missense mutation and heteroallelic deletion in MUSK. Neuromuscul Disord 24:31–35PubMedCentralCrossRefPubMedGoogle Scholar
  25. 25.
    Okada K, Inoue A, Okada M et al (2006) The muscle protein Dok-7 is essential for neuromuscular synaptogenesis. Science 312:1802–1805CrossRefPubMedGoogle Scholar
  26. 26.
    Beeson D, Higuchi O, Palace J et al (2006) Dok-7 mutations underlie a neuromuscular junction synaptopathy. Science 313:1975–1978CrossRefPubMedGoogle Scholar
  27. 27.
    Klein A, Pitt MC, McHugh JC et al (2013) DOK7 congenital myasthenic syndrome in childhood: early diagnostic clues in 23 children. Neuromuscul Disord 23:883–891CrossRefPubMedGoogle Scholar
  28. 28.
    Cossins J, Liu WW, Belaya K et al (2012) The spectrum of mutations that underlie the neuromuscular junction synaptopathy in DOK7 congenital myasthenic syndrome. Hum Mol Genet 21:3765–3775CrossRefPubMedGoogle Scholar
  29. 29.
    Witting N, Vissing J (2014) Pharmacologic treatment of downstream of tyrosine kinase 7 congenital myasthenic syndrome. JAMA Neurol 71:350–354CrossRefPubMedGoogle Scholar
  30. 30.
    Ohno K, Brengman J, Tsujino a, Engel aG (1998) Human endplate acetylcholinesterase deficiency caused by mutations in the collagen-like tail subunit (ColQ) of the asymmetric enzyme. Proc Natl Acad Sci USA 95:9654–9659PubMedCentralCrossRefPubMedGoogle Scholar
  31. 31.
    Ito M, Suzuki Y, Okada T et al (2012) Protein-anchoring strategy for delivering acetylcholinesterase to the neuromuscular junction. Mol Ther 20:1384–1392PubMedCentralCrossRefPubMedGoogle Scholar
  32. 32.
    Nakata T, Ito M, Azuma Y et al (2013) Mutations in the C-terminal domain of ColQ in endplate acetylcholinesterase deficiency compromise ColQ-MuSK interaction. Hum Mutat 34:997–1004CrossRefPubMedGoogle Scholar
  33. 33.
    Arredondo J, Lara M, Ng F et al (2013) COOH-terminal collagen Q (COLQ) mutants causing human deficiency of endplate acetylcholinesterase impair the interaction of ColQ with proteins of the basal lamina. Hum Genet 133:599–616PubMedCentralCrossRefPubMedGoogle Scholar
  34. 34.
    Matlik HN, Milhem RM, Saadeldin IY et al (2014) Clinical and molecular analysis of a novel COLQ missense mutation causing congenital myasthenic syndrome in a Syrian family. Pediatr Neurol 51:165–169CrossRefPubMedGoogle Scholar
  35. 35.
    Ohno K, Tsujino a, Brengman JM et al (2001) Choline acetyltransferase mutations cause myasthenic syndrome associated with episodic apnea in humans. Proc Natl Acad Sci USA 98:2017–2022PubMedCentralCrossRefPubMedGoogle Scholar
  36. 36.
    Schara U, Christen H-J, Durmus H et al (2010) Long-term follow-up in patients with congenital myasthenic syndrome due to CHAT mutations. Eur J Paediatr Neurol 14:326–333CrossRefPubMedGoogle Scholar
  37. 37.
    Shen X-M, Crawford TO, Brengman J et al (2011) Functional consequences and structural interpretation of mutations of human choline acetyltransferase. Hum Mutat 32:1259–1267PubMedCentralCrossRefPubMedGoogle Scholar
  38. 38.
    Kim N, Stiegler AL, Cameron TO et al (2008) Lrp4 is a receptor for Agrin and forms a complex with MuSK. Cell 135:334–342PubMedCentralCrossRefPubMedGoogle Scholar
  39. 39.
    Zhang W, Coldefy A-S, Hubbard SR, Burden SJ (2011) Agrin binds to the N-terminal region of Lrp4 protein and stimulates association between Lrp4 and the first immunoglobulin-like domain in muscle-specific kinase (MuSK). J Biol Chem 286:40624–40630PubMedCentralCrossRefPubMedGoogle Scholar
  40. 40.
    Ohkawara B, Cabrera-Serrano M, Nakata T et al (2013) LRP4 third β-propeller domain mutations cause novel congenital myasthenia by compromising agrin-mediated musk signaling in a position-specific manner. Hum Mol Genet 23:1856–1868PubMedCentralCrossRefPubMedGoogle Scholar
  41. 41.
    Richard P, Goillot E, Huze C et al (2009) Identification of an agrin mutation that causes congenital myasthenia and affects synapse function. Am J Hum Genet 85:155–167PubMedCentralCrossRefPubMedGoogle Scholar
  42. 42.
    Maselli RA, Fernandez JM, Arredondo J et al (2012) LG2 agrin mutation causing severe congenital myasthenic syndrome mimics functional characteristics of non-neural (z-) agrin. Hum Genet 131:1123–1135CrossRefPubMedGoogle Scholar
  43. 43.
    Nicole S, Chaouch A, Torbergsen T et al (2014) Agrin mutations lead to a congenital myasthenic syndrome with distal muscle weakness and atrophy. Brain 137:2429–2443CrossRefPubMedGoogle Scholar
  44. 44.
    Lone AM, Nolte WM, Tinoco AD, Saghatelian A (2010) Peptidomics of the prolyl peptidases. AAPS J 12:483–491PubMedCentralCrossRefPubMedGoogle Scholar
  45. 45.
    Martens K, Derua R, Meulemans S et al (2006) PREPL: a putative novel oligopeptidase propelled into the limelight. Biol Chem 387:879–883CrossRefPubMedGoogle Scholar
  46. 46.
    Régal L, Shen X-M, Selcen D et al (2014) PREPL deficiency with or without cystinuria causes a novel myasthenic syndrome. Neurology 82:1254–1260PubMedCentralCrossRefPubMedGoogle Scholar
  47. 47.
    Kim M-H, Hersh LB (2004) The vesicular acetylcholine transporter interacts with clathrin-associated adaptor complexes AP-1 and AP-2. J Biol Chem 279:12580–12587CrossRefPubMedGoogle Scholar
  48. 48.
    Radhakrishnan K, Baltes J, Creemers JWM, Schu P (2013) Trans-Golgi network morphology and sorting is regulated by prolyl-oligopeptidase-like protein PREPL and the AP-1 complex subunit μ1A. J Cell Sci 126:1155–1163CrossRefPubMedGoogle Scholar
  49. 49.
    Jaeken J, Matthijs G (2001) Congenital disorders of glycosylation. Annu Rev Genomics Hum Genet 2:129–151CrossRefPubMedGoogle Scholar
  50. 50.
    Wu X, Rush JS, Karaoglu D et al (2003) Deficiency of UDP-GlcNAc:Dolichol Phosphate N-Acetylglucosamine-1 Phosphate Transferase (DPAGT1) causes a novel congenital disorder of Glycosylation Type I. J Hum Mutat 22:144–150CrossRefGoogle Scholar
  51. 51.
    Thiel C, Schwarz M, Peng J et al (2003) A new type of congenital disorders of glycosylation (CDG-Ii) provides new insights into the early steps of dolichol-linked oligosaccharide biosynthesis. J Biol Chem 278:22498–22505CrossRefPubMedGoogle Scholar
  52. 52.
    Haltiwanger RS, Lowe JB (2004) Role of glycosylation in development. Annu Rev Biochem 73:491–537CrossRefPubMedGoogle Scholar
  53. 53.
    Velina Guergueltcheva, Jacqueline Palace, David Beeson HL (2011) Congenital myasthenic syndrome with tubular aggregates caused by GFPT1 mutations. J NeurolGoogle Scholar
  54. 54.
    Selcen D, Shen X-M, Milone M et al (2013) GFPT1-myasthenia: clinical, structural, and electrophysiologic heterogeneity. Neurology 81:370–378PubMedCentralCrossRefPubMedGoogle Scholar
  55. 55.
    Huh S-Y, Kim H-S, Jang H-J et al (2012) Limb-girdle myasthenia with tubular aggregates associated with novel GFPT1 mutations. Muscle Nerve 46:600–604CrossRefPubMedGoogle Scholar
  56. 56.
    Martin PT (2003) Glycobiology of the neuromuscular junction. J Neurocytol 32:915–929CrossRefPubMedGoogle Scholar
  57. 57.
    Zoltowska K, Webster R, Finlayson S et al (2013) Mutations in GFPT1 that underlie limb-girdle congenital myasthenic syndrome result in reduced cell-surface expression of muscle AChR. Hum Mol Genet 22:2905–2913CrossRefPubMedGoogle Scholar
  58. 58.
    Bretthauer RK (2009) Structure, expression, and regulation of UDP-GlcNAc: dolichol phosphate GlcNAc-1-phosphate transferase (DPAGT1). Curr Drug Targets 10:477–482CrossRefPubMedGoogle Scholar
  59. 59.
    Merlie JP, Sebbane R, Tzartos S, Lindstrom J (1982) Inhibition of glycosylation with tunicamycin blocks assembly of newly synthesized acetylcholine receptor subunits in muscle cells. J Biol Chem 257:2694–2701PubMedGoogle Scholar
  60. 60.
    Selcen D, Shen X, Brengman J (2014) expression studies DPAGT1 myasthenia and myopathy. Neurology 82:1822–1830PubMedCentralCrossRefPubMedGoogle Scholar
  61. 61.
    Basiri K, Belaya K, Liu WW et al (2013) Clinical features in a large Iranian family with a limb-girdle congenital myasthenic syndrome due to a mutation in DPAGT1. Neuromuscul Disord 23:469–472PubMedCentralCrossRefPubMedGoogle Scholar
  62. 62.
    Jackson BJ, Kukuruzinska MA, Robbins P (1993) Biosynthesis of asparagine-linked oligosaccharides in Saccharomyces cerevisiae: the alg2 mutation. Glycobiology 3:357–364CrossRefPubMedGoogle Scholar
  63. 63.
    Lu J, Takahashi T, Ohoka A et al (2012) Alg14 organizes the formation of a multiglycosyltransferase complex involved in initiation of lipid-linked oligosaccharide biosynthesis. Glycobiology 22:504–516CrossRefPubMedGoogle Scholar
  64. 64.
    Monies DM, Al-Hindi HN, Al-Muhaizea Ma et al (2014) Clinical and pathological heterogeneity of a congenital disorder of glycosylation manifesting as a myasthenic/myopathic syndrome. Neuromuscul Disord 24:353–359CrossRefPubMedGoogle Scholar
  65. 65.
    Rodriguez Cruz P, Sewry C, Beeson D et al (2014) Science direct congenital myopathies with secondary neuromuscular transmission defects.A case report and review of the literature. Neuromuscul Disord. doi: 10.1016/j.nmd.2014.07.005 Google Scholar
  66. 66.
    Illingworth M, Main M, Pitt M, et al. RYR1-related congenital myopathy with fatigable weakness, responding to pyridostigimineGoogle Scholar
  67. 67.
    Munot P, Lashley D, Jungbluth H et al (2010) Congenital fibre type disproportion associated with mutations in the tropomyosin 3 (TPM3) gene mimicking congenital myasthenia. Neuromuscul Disord 20:796–800CrossRefPubMedGoogle Scholar
  68. 68.
    Robb Sa, Sewry Ca, Dowling JJ et al (2011) Impaired neuromuscular transmission and response to acetylcholinesterase inhibitors in centronuclear myopathies. Neuromuscul Disord 21:379–386CrossRefPubMedGoogle Scholar
  69. 69.
    Liewluck T, Shen X-M, Milone M, Engel AG (2012) Endplate structure and parameters of neuromuscular transmission in sporadic centronuclear myopathy associated with myasthenia. Neuromuscul Disord 21:387–395CrossRefGoogle Scholar
  70. 70.
    Gibbs EM, Clarke NF, Rose K et al (2013) Neuromuscular junction abnormalities in DNM2-related centronuclear myopathy. J Mol Med (Berl) 91:727–737CrossRefGoogle Scholar
  71. 71.
    Servais L, Baudoin H, Zehrouni K et al (2013) Pregnancy in congenital myasthenic syndrome. J Neurol 260:815–819CrossRefPubMedGoogle Scholar
  72. 72.
    Lorenzoni PJ, Scola RH, Kay CSK et al (2013) Salbutamol therapy in congenital myasthenic syndrome due to DOK7 mutation. J Neurol Sci 331:155–157CrossRefPubMedGoogle Scholar
  73. 73.
    Burke G, Hiscock A, Klein A et al (2013) Salbutamol benefits children with congenital myasthenic syndrome due to DOK7 mutations. Neuromuscul Disord 23:170–175CrossRefPubMedGoogle Scholar
  74. 74.
    Lashley D, Palace J, Jayawant S et al (2010) Ephedrine treatment in congenital myasthenic syndrome due to mutations in DOK7. Neurology 74:1517–1523PubMedCentralCrossRefPubMedGoogle Scholar
  75. 75.
    Sadeh M, Xin-Ming SEA (2012) Beneficial effect of albuterol in CMS with epsilon subunit mutations. Muscle Nerve 44:289–291CrossRefGoogle Scholar
  76. 76.
    Finlayson S, Palace J, Belaya K et al (2013) Clinical features of congenital myasthenic syndrome due to mutations in DPAGT1. J Neurol Neurosurg Psychiatry 84:1119–1125CrossRefPubMedGoogle Scholar
  77. 77.
    Liewluck T, Selcen D, Engel AG (2011) Beneficial effects of Albuterol in congenital endplate acetylcholinesterase deficiency and DOK-7 myasthenia. Muscle Nerve 44:789–794PubMedCentralCrossRefPubMedGoogle Scholar
  78. 78.
    Wargon I, Richard P, Kuntzer T et al (2012) Long-term follow-up of patients with congenital myasthenic syndrome caused by COLQ mutations. Neuromuscul Disord 22:318–324CrossRefPubMedGoogle Scholar
  79. 79.
    Mihaylova V, Müller JS, Vilchez JJ et al (2008) Clinical and molecular genetic findings in COLQ-mutant congenital myasthenic syndromes. Brain 131:747–759CrossRefPubMedGoogle Scholar
  80. 80.
    Guven A, Demirci M, Anlar B (2012) Recurrent COLQ mutation in congenital myasthenic syndrome. Pediatr Neurol 46:253–256CrossRefPubMedGoogle Scholar
  81. 81.
    Duran GS, Uzunhan TA, Ekici B et al (2013) Severe scoliosis in a patient with COLQ mutation and congenital myasthenic syndrome: a clue for diagnosis. Acta Neurol Belg 113:531–532CrossRefPubMedGoogle Scholar
  82. 82.
    Bestue-Cardiel M, de Cabezón-Alvarez a Sáenz, Capablo-Liesa JL et al (2005) Congenital endplate acetylcholinesterase deficiency responsive to ephedrine. Neurology 65:144–146CrossRefPubMedGoogle Scholar
  83. 83.
    Choi K-R, Berrera M, Reischl M et al (2012) Rapsyn mediates subsynaptic anchoring of PKA type I and stabilisation of acetylcholine receptor in vivo. J Cell Sci 125:714–723CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2014

Authors and Affiliations

  • Pedro M. Rodríguez Cruz
    • 1
  • Jacqueline Palace
    • 1
  • David Beeson
    • 1
    • 2
    Email author
  1. 1.Nuffield Department of Clinical NeurosciencesUniversity of OxfordOxfordUK
  2. 2.Neurosciences Group, Weatherall Institute of Molecular MedicineUniversity of Oxford, The John Radcliffe HospitalOxfordUK

Personalised recommendations